BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
2.560
+0.550 (27.36%)
At close: Mar 3, 2025, 4:00 PM
2.260
-0.300 (-11.72%)
Pre-market: Mar 4, 2025, 8:00 AM EST
BioCardia Revenue
BioCardia had revenue of $71.00K in the twelve months ending September 30, 2024, down -87.54% year-over-year. In the year 2023, BioCardia had annual revenue of $477.00K, down -64.72%.
Revenue (ttm)
$71.00K
Revenue Growth
-87.54%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
n/a
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
Dec 31, 2019 | 710.00K | 85.00K | 13.60% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BCDA News
- 4 days ago - BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions - GlobeNewsWire
- 18 days ago - BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) - GlobeNewsWire
- 5 weeks ago - BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions - GlobeNewsWire
- 3 months ago - BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure - GlobeNewsWire
- 3 months ago - BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - BioCardia Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 6 months ago - BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 6 months ago - BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family - GlobeNewsWire